Meindert Boysen, PharmD, is the director for the technology appraisal and the highly specialized technologies programs at the National Institute for Health and Care Excellence (NICE) in England, UK. Meindert is also responsible for the Patient Access Schemes Liaison Unit, and the NICE side of the Cancer Drugs Fund.
Meindert graduated as a pharmacist in the Netherlands, and has since completed a masters in health policy planning and financing at the London School of Hygiene and Tropical Medicine and the London School of Economics and Political Science.
He has worked in hospital pharmacy, in pharmaceutical industry (Eli Lilly & Co), for the King's Fund, and NICE. In his time at NICE, Meindert has been leading on the move to 'single technology appraisals.' on bringing in the program for 'ultra-orphan' drugs, on the development of the plans for value-based assessment, on the arrangements for the new cancer drugs fund, and most recently on the proposals regarding consideration of budget impact, fast-track appraisals and highly specialized technologies. The latter two in close collaboration with the commissioner (payer) of care; NHS England.
Meindert is a skilled communicator, effective negotiator, and extremely dedicated to ensuring that the programs he leads deliver on their key performance targets and budgets.